{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T15:43:03Z","timestamp":1774626183616,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"DOI":"10.1186\/s12920-025-02192-7","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T16:37:46Z","timestamp":1753115866000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The prognostic significance and Immunomodulatory role of SCGB3A1 expression in stage I lung adenocarcinoma"],"prefix":"10.1186","volume":"18","author":[{"given":"Xin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ShiNing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujin","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XinYu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Ao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LeQi","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"issue":"3","key":"2192_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. 1 global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"2192_CR2","unstructured":"The biology and management of non-small cell lung cancer - PubMed. Accessed May 19. 2024. https:\/\/pubmed.ncbi.nlm.nih.gov\/29364287\/"},{"issue":"1","key":"2192_CR3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.chest.2016.10.010","volume":"151","author":"FC Detterbeck","year":"2017","unstructured":"Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. 3 the eighth edition lung Cancer stage classification. Chest. 2017;151(1):193\u2013203. https:\/\/doi.org\/10.1016\/j.chest.2016.10.010.","journal-title":"Chest"},{"key":"2192_CR4","unstructured":"The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer - PubMed. Accessed May 19. 2024. https:\/\/pubmed.ncbi.nlm.nih.gov\/26762738\/"},{"key":"2192_CR5","unstructured":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial - PubMed. Accessed May 19. 2024. https:\/\/pubmed.ncbi.nlm.nih.gov\/34555333\/"},{"key":"2192_CR6","unstructured":"Neoadjuvant PD-. 1 Blockade in Resectable Lung Cancer - PubMed. Accessed May 19, 2024. https:\/\/pubmed.ncbi.nlm.nih.gov\/29658848\/"},{"key":"2192_CR7","unstructured":"Neoadjuvant and Adjuvant Immunotherapy: Opening New Horizons for Patients With Early-Stage Non-small Cell Lung Cancer - PubMed. Accessed May 19. 2024. https:\/\/pubmed.ncbi.nlm.nih.gov\/33163406\/"},{"key":"2192_CR8","unstructured":"PD-1 Blockade in Early-Stage Lung Cancer - PubMed. Accessed May 19. 2024. https:\/\/pubmed.ncbi.nlm.nih.gov\/30355264\/"},{"key":"2192_CR9","unstructured":"Microenvironmental regulation of tumor progression and metastasis - PubMed. Accessed May 19. 2024. https:\/\/pubmed.ncbi.nlm.nih.gov\/24202395\/"},{"key":"2192_CR10","unstructured":"Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline - PubMed. Accessed May 19. 2024. https:\/\/pubmed.ncbi.nlm.nih.gov\/35816666\/"},{"key":"2192_CR11","unstructured":"Multi-omics Data Analyses Construct TME and Identify the Immune-Related Prognosis Signatures in Human LUAD - PubMed. Accessed May 19. 2024. https:\/\/pubmed.ncbi.nlm.nih.gov\/32805489\/"},{"key":"2192_CR12","unstructured":"HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells - PubMed. Accessed May 19. 2024. https:\/\/pubmed.ncbi.nlm.nih.gov\/11481438\/"},{"issue":"9","key":"2192_CR13","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1158\/1541-7786.489.2.9","volume":"2","author":"I Krop","year":"2004","unstructured":"Krop I, Player A, Tablante A, et al. 13 frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types. Mol Cancer Res MCR. 2004;2(9):489\u201394.","journal-title":"Mol Cancer Res MCR"},{"issue":"4","key":"2192_CR14","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/ijc.20622","volume":"113","author":"H Shigematsu","year":"2005","unstructured":"Shigematsu H, Suzuki M, Takahashi T, et al. 14 aberrant methylation of HIN-1 (high in normal-1) is a frequent event in many human malignancies. Int J Cancer. 2005;113(4):600\u20134. https:\/\/doi.org\/10.1002\/ijc.20622.","journal-title":"Int J Cancer"},{"issue":"4","key":"2192_CR15","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1158\/1078-0432.ccr-1174-03","volume":"10","author":"A Marchetti","year":"2004","unstructured":"Marchetti A, Barassi F, Martella C, et al. 15 down regulation of high in normal-1 (HIN-1) is a frequent event in stage I non-small cell lung cancer and correlates with poor clinical outcome. Clin Cancer Res Off J Am Assoc Cancer Res. 2004;10(4):1338\u201343. https:\/\/doi.org\/10.1158\/1078-0432.ccr-1174-03.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2192_CR16","unstructured":"Accessed. May 20, 2024. https:\/\/pubmed.ncbi.nlm.nih.gov\/16266985\/"},{"key":"2192_CR17","unstructured":"IFN-gamma down-regulates Secretoglobin 3A1 gene expression - PubMed. Accessed May 20. 2024. https:\/\/pubmed.ncbi.nlm.nih.gov\/19135978\/"},{"issue":"2","key":"2192_CR18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.20892\/j.issn.2095-3941.2023.0401","volume":"21","author":"J Wang","year":"2023","unstructured":"Wang J, Wu L. 18 First-line immunotherapy for advanced non-small cell lung cancer: current progress and future prospects. Cancer Biol Med. 2023;21(2):117\u201324. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2023.0401.","journal-title":"Cancer Biol Med"},{"key":"2192_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.lungcan.2021.04.007","volume":"156","author":"D Waterhouse","year":"2021","unstructured":"Waterhouse D, Lam J, Betts KA, et al. 19 Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer. Lung Cancer Amst Neth. 2021;156:41\u20139. https:\/\/doi.org\/10.1016\/j.lungcan.2021.04.007.","journal-title":"Lung Cancer Amst Neth"},{"issue":"2","key":"2192_CR20","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.21037\/jtd-23-1890","volume":"16","author":"C Liang","year":"2024","unstructured":"Liang C, Pan W, Zhou Z, Liu X. 20 identification of prognostic biomarkers of smoking-related lung cancer. J Thorac Dis. 2024;16(2):1438\u201349. https:\/\/doi.org\/10.21037\/jtd-23-1890.","journal-title":"J Thorac Dis"},{"key":"2192_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/bs.mie.2017.03.026","volume":"592","author":"AW Malaby","year":"2017","unstructured":"Malaby AW, Martin SK, Wood RD, Doubli\u00e9 S. 21 expression and structural analyses of human DNA polymerase \u03b8 (POLQ). Methods Enzymol. 2017;592:103\u201321. https:\/\/doi.org\/10.1016\/bs.mie.2017.03.026.","journal-title":"Methods Enzymol"},{"issue":"1","key":"2192_CR22","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1186\/s12935-021-02178-2","volume":"21","author":"Q Pan","year":"2021","unstructured":"Pan Q, Wang L, Liu Y, et al. 22 knockdown of POLQ interferes the development and progression of hepatocellular carcinoma through regulating cell proliferation, apoptosis and migration. Cancer Cell Int. 2021;21(1):482. https:\/\/doi.org\/10.1186\/s12935-021-02178-2.","journal-title":"Cancer Cell Int"},{"key":"2192_CR23","doi-asserted-by":"publisher","first-page":"1242448","DOI":"10.3389\/fnins.2023.1242448","volume":"17","author":"X Wu","year":"2023","unstructured":"Wu X, Li Z, Wang ZQ, Xu X. 23 the neurological and non-neurological roles of the primary microcephaly-associated protein ASPM. Front Neurosci. 2023;17:1242448. https:\/\/doi.org\/10.3389\/fnins.2023.1242448.","journal-title":"Front Neurosci"},{"issue":"4","key":"2192_CR24","doi-asserted-by":"publisher","first-page":"e61664","DOI":"10.1371\/journal.pone.0061664","volume":"8","author":"PF Hung","year":"2013","unstructured":"Hung PF, Hong TM, Hsu YC, et al. 24 the motor protein KIF14 inhibits tumor growth and cancer metastasis in lung adenocarcinoma. PLoS ONE. 2013;8(4):e61664. https:\/\/doi.org\/10.1371\/journal.pone.0061664.","journal-title":"PLoS ONE"},{"key":"2192_CR25","doi-asserted-by":"publisher","first-page":"720645","DOI":"10.3389\/fmolb.2021.720645","volume":"8","author":"B Fan","year":"2021","unstructured":"Fan B, Ji K, Bu Z, et al. 25 ARHGAP11A is a prognostic biomarker and correlated with immune infiltrates in gastric Cancer. Front Mol Biosci. 2021;8:720645. https:\/\/doi.org\/10.3389\/fmolb.2021.720645.","journal-title":"Front Mol Biosci"},{"issue":"2","key":"2192_CR26","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s10549-020-05962-2","volume":"185","author":"D Koyuncu","year":"2021","unstructured":"Koyuncu D, Sharma U, Goka ET, Lippman ME. 26 spindle assembly checkpoint gene BUB1B is essential in breast cancer cell survival. Breast Cancer Res Treat. 2021;185(2):331\u201341. https:\/\/doi.org\/10.1007\/s10549-020-05962-2.","journal-title":"Breast Cancer Res Treat"},{"key":"2192_CR27","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.3389\/fimmu.2020.01749","volume":"11","author":"MT Masucci","year":"2020","unstructured":"Masucci MT, Minopoli M, Del Vecchio S, Carriero MV. 27 the emerging role of neutrophil extracellular traps (NETs) in tumor progression and metastasis. Front Immunol. 2020;11:1749. https:\/\/doi.org\/10.3389\/fimmu.2020.01749.","journal-title":"Front Immunol"},{"issue":"17","key":"2192_CR28","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.3390\/cancers13174495","volume":"13","author":"U Demkow","year":"2021","unstructured":"Demkow U. 28 neutrophil extracellular traps (NETs) in Cancer invasion, evasion and metastasis. Cancers. 2021;13(17):4495. https:\/\/doi.org\/10.3390\/cancers13174495.","journal-title":"Cancers"},{"issue":"1","key":"2192_CR29","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s13046-021-02013-6","volume":"40","author":"D Yang","year":"2021","unstructured":"Yang D, Liu J. 29 neutrophil extracellular traps: A new player in Cancer metastasis and therapeutic target. J Exp Clin Cancer Res CR. 2021;40(1):233. https:\/\/doi.org\/10.1186\/s13046-021-02013-6.","journal-title":"J Exp Clin Cancer Res CR"},{"key":"2192_CR30","doi-asserted-by":"publisher","first-page":"1315490","DOI":"10.3389\/fimmu.2023.1315490","volume":"14","author":"C Amantini","year":"2023","unstructured":"Amantini C, Morelli MB. 30 editorial: calcium signaling in cancer immunity. Front Immunol. 2023;14:1315490. https:\/\/doi.org\/10.3389\/fimmu.2023.1315490.","journal-title":"Front Immunol"},{"issue":"6","key":"2192_CR31","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1039\/d1sm01618k","volume":"18","author":"C Liang","year":"2022","unstructured":"Liang C, Huang M, Li T, et al. 31 towards an integrative Understanding of cancer mechanobiology: calcium, YAP, and MicroRNA under biophysical forces. Soft Matter. 2022;18(6):1112\u201348. https:\/\/doi.org\/10.1039\/d1sm01618k.","journal-title":"Soft Matter"},{"issue":"3","key":"2192_CR32","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s13238-010-0019-9","volume":"1","author":"P Huang","year":"2010","unstructured":"Huang P, Han J, Hui L. 33 MAPK signaling in inflammation-associated cancer development. Protein Cell. 2010;1(3):218\u201326. https:\/\/doi.org\/10.1007\/s13238-010-0019-9.","journal-title":"Protein Cell"},{"issue":"22","key":"2192_CR33","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1002\/cncr.28864","volume":"120","author":"M Burotto","year":"2014","unstructured":"Burotto M, Chiou VL, Lee JM, Kohn EC. 32 the MAPK pathway across different malignancies: a new perspective. Cancer. 2014;120(22):3446\u201356. https:\/\/doi.org\/10.1002\/cncr.28864.","journal-title":"Cancer"},{"issue":"50","key":"2192_CR34","doi-asserted-by":"publisher","first-page":"82254","DOI":"10.18632\/oncotarget.12672","volume":"7","author":"L Chen","year":"2016","unstructured":"Chen L, Kurtyka CA, Welsh EA, et al. 34 Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma. Oncotarget. 2016;7(50):82254\u201365. https:\/\/doi.org\/10.18632\/oncotarget.12672.","journal-title":"Oncotarget"},{"issue":"1","key":"2192_CR35","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1186\/s12885-023-10865-8","volume":"23","author":"J Li","year":"2023","unstructured":"Li J, Bi W, Lu F, et al. 35 prognostic role of E2F1 gene expression in human cancer: a meta-analysis. BMC Cancer. 2023;23(1):509. https:\/\/doi.org\/10.1186\/s12885-023-10865-8.","journal-title":"BMC Cancer"},{"issue":"1","key":"2192_CR36","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12859-023-05268-2","volume":"24","author":"H Li","year":"2023","unstructured":"Li H, Yang L, Wang Y, et al. 36 integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis. BMC Bioinformatics. 2023;24(1):155. https:\/\/doi.org\/10.1186\/s12859-023-05268-2.","journal-title":"BMC Bioinformatics"},{"issue":"8","key":"2192_CR37","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.3390\/ijms21082921","volume":"21","author":"M Oshi","year":"2020","unstructured":"Oshi M, Takahashi H, Tokumaru Y, et al. 37 G2M cell cycle pathway score as a prognostic biomarker of metastasis in Estrogen receptor (ER)-Positive breast Cancer. Int J Mol Sci. 2020;21(8):2921. https:\/\/doi.org\/10.3390\/ijms21082921.","journal-title":"Int J Mol Sci"},{"key":"2192_CR38","doi-asserted-by":"publisher","first-page":"894338","DOI":"10.3389\/fmed.2022.894338","volume":"9","author":"X Ruan","year":"2022","unstructured":"Ruan X, Ye Y, Cheng W, et al. 38 Multi-Omics integrative analysis of lung adenocarcinoma: an in Silico profiling for precise medicine. Front Med. 2022;9:894338. https:\/\/doi.org\/10.3389\/fmed.2022.894338.","journal-title":"Front Med"},{"issue":"3","key":"2192_CR39","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3390\/cells11030349","volume":"11","author":"D Segura-Villalobos","year":"2022","unstructured":"Segura-Villalobos D, Ram\u00edrez-Moreno IG, Mart\u00ednez-Aguilar M, et al. Mast Cell-Tumor interactions: molecular mechanisms of recruitment, intratumoral communication and potential therapeutic targets for tumor growth. Cells. 2022;11(3):349. https:\/\/doi.org\/10.3390\/cells11030349.","journal-title":"Cells"},{"issue":"1","key":"2192_CR40","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00005-023-00676-x","volume":"71","author":"D Ribatti","year":"2023","unstructured":"Ribatti D. Mast cells and resistance to immunotherapy in Cancer. Arch Immunol Ther Exp (Warsz). 2023;71(1):11. https:\/\/doi.org\/10.1007\/s00005-023-00676-x.","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"1","key":"2192_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1158\/2326-6066.CIR-13-0196","volume":"2","author":"BP Davis","year":"2014","unstructured":"Davis BP, Rothenberg ME. Eosinophils and cancer. Cancer Immunol Res. 2014;2(1):1\u20138. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0196.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2192_CR42","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1186\/s12967-023-04418-7","volume":"21","author":"S Ghaffari","year":"2023","unstructured":"Ghaffari S, Rezaei N. Eosinophils in the tumor microenvironment: implications for cancer immunotherapy. J Transl Med. 2023;21(1):551. https:\/\/doi.org\/10.1186\/s12967-023-04418-7.","journal-title":"J Transl Med"},{"issue":"4","key":"2192_CR43","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.trecan.2022.12.007","volume":"9","author":"N Guti\u00e9rrez-Melo","year":"2023","unstructured":"Guti\u00e9rrez-Melo N, Baumjohann D. T follicular helper cells in cancer. Trends Cancer. 2023;9(4):309\u201325. https:\/\/doi.org\/10.1016\/j.trecan.2022.12.007.","journal-title":"Trends Cancer"},{"issue":"6","key":"2192_CR44","doi-asserted-by":"publisher","first-page":"e002588","DOI":"10.1136\/jitc-2021-002588","volume":"9","author":"D Baumjohann","year":"2021","unstructured":"Baumjohann D, Brossart P. T follicular helper cells: linking cancer immunotherapy and immune-related adverse events. J Immunother Cancer. 2021;9(6):e002588. https:\/\/doi.org\/10.1136\/jitc-2021-002588.","journal-title":"J Immunother Cancer"},{"issue":"11","key":"2192_CR45","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1002\/cyto.a.23280","volume":"91","author":"SA Marsh","year":"2017","unstructured":"Marsh SA, Arthur HM, Spyridopoulos I. 45 the secret life of nonclassical monocytes. Cytom Part J Int Soc Anal Cytol. 2017;91(11):1055\u20138. https:\/\/doi.org\/10.1002\/cyto.a.23280.","journal-title":"Cytom Part J Int Soc Anal Cytol"},{"key":"2192_CR46","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3389\/fcvm.2017.00080","volume":"4","author":"K Buscher","year":"2017","unstructured":"Buscher K, Marcovecchio P, Hedrick CC, Ley K. 46 patrolling mechanics of Non-Classical monocytes in vascular inflammation. Front Cardiovasc Med. 2017;4:80. https:\/\/doi.org\/10.3389\/fcvm.2017.00080.","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"2192_CR47","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s10555-021-09958-2","volume":"40","author":"V Delprat","year":"2021","unstructured":"Delprat V, Michiels C. 47 A bi-directional dialog between vascular cells and monocytes\/macrophages regulates tumor progression. Cancer Metastasis Rev. 2021;40(2):477\u2013500. https:\/\/doi.org\/10.1007\/s10555-021-09958-2.","journal-title":"Cancer Metastasis Rev"},{"key":"2192_CR48","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.3389\/fonc.2020.01399","volume":"10","author":"M Kiss","year":"2020","unstructured":"Kiss M, Caro AA, Raes G, Laoui D. 48 systemic reprogramming of monocytes in Cancer. Front Oncol. 2020;10:1399. https:\/\/doi.org\/10.3389\/fonc.2020.01399.","journal-title":"Front Oncol"},{"issue":"10","key":"2192_CR49","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3390\/cells13100794","volume":"13","author":"A Kula","year":"2024","unstructured":"Kula A, Koszewska D, Kot A, et al. 49 the importance of HHLA2 in solid Tumors-A review of the literature. Cells. 2024;13(10):794. https:\/\/doi.org\/10.3390\/cells13100794.","journal-title":"Cells"},{"issue":"1","key":"2192_CR50","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s12967-022-03520-6","volume":"20","author":"N Sun","year":"2022","unstructured":"Sun N, Luo Y, Zheng B, et al. 50 A novel immune checkpoints-based signature to predict prognosis and response to immunotherapy in lung adenocarcinoma. J Transl Med. 2022;20(1):332. https:\/\/doi.org\/10.1186\/s12967-022-03520-6.","journal-title":"J Transl Med"},{"issue":"1","key":"2192_CR51","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12885-024-12014-1","volume":"24","author":"M Xu","year":"2024","unstructured":"Xu M, Li C, Xiang L, et al. 51 assessing the causal relationship between 731 immunophenotypes and the risk of lung cancer: a bidirectional Mendelian randomization study. BMC Cancer. 2024;24(1):270. https:\/\/doi.org\/10.1186\/s12885-024-12014-1.","journal-title":"BMC Cancer"},{"key":"2192_CR52","unstructured":"A Systematic Immune and Prognostic Analysis of CD48 Interaction with Tumor Microenvironment in Pan-Cancer - PubMed. Accessed May 31, 2024. https:\/\/pubmed.ncbi.nlm.nih.gov\/38021043\/"},{"key":"2192_CR53","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1515\/med-2019-0076","volume":"14","author":"C Zhang","year":"2019","unstructured":"Zhang C, Hao X. 53 prognostic significance of CD276 in Non-small cell lung Cancer. Open Med Wars Pol. 2019;14:805\u201312. https:\/\/doi.org\/10.1515\/med-2019-0076.","journal-title":"Open Med Wars Pol"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-025-02192-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-025-02192-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-025-02192-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T16:30:00Z","timestamp":1757262600000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/s12920-025-02192-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2192"],"URL":"https:\/\/doi.org\/10.1186\/s12920-025-02192-7","relation":{},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"119"}}